110 related articles for article (PubMed ID: 22159143)
41. T cell suppression by naturally occurring HLA-G-expressing regulatory CD4+ T cells is IL-10-dependent and reversible.
Huang YH; Zozulya AL; Weidenfeller C; Schwab N; Wiendl H
J Leukoc Biol; 2009 Aug; 86(2):273-81. PubMed ID: 19401389
[TBL] [Abstract][Full Text] [Related]
42. CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus.
Kuhn A; Beissert S; Krammer PH
Arch Dermatol Res; 2009 Jan; 301(1):71-81. PubMed ID: 18985367
[TBL] [Abstract][Full Text] [Related]
43. CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis.
Kumar M; Putzki N; Limmroth V; Remus R; Lindemann M; Knop D; Mueller N; Hardt C; Kreuzfelder E; Grosse-Wilde H
J Neuroimmunol; 2006 Nov; 180(1-2):178-84. PubMed ID: 17011048
[TBL] [Abstract][Full Text] [Related]
44. Engagement of TLR2 reverses the suppressor function of conjunctiva CD4+CD25+ regulatory T cells and promotes herpes simplex virus epitope-specific CD4+CD25- effector T cell responses.
Dasgupta G; Chentoufi AA; You S; Falatoonzadeh P; Urbano LA; Akhtarmalik A; Nguyen K; Ablabutyan L; Nesburn AB; BenMohamed L
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3321-33. PubMed ID: 21273544
[TBL] [Abstract][Full Text] [Related]
45. The inhibitory cytokine IL-35 contributes to regulatory T-cell function.
Collison LW; Workman CJ; Kuo TT; Boyd K; Wang Y; Vignali KM; Cross R; Sehy D; Blumberg RS; Vignali DA
Nature; 2007 Nov; 450(7169):566-9. PubMed ID: 18033300
[TBL] [Abstract][Full Text] [Related]
46. Deficient and dysfunctional regulatory T cells in the lungs of chronic beryllium disease subjects.
Mack DG; Lanham AM; Falta MT; Palmer BE; Maier LA; Fontenot AP
Am J Respir Crit Care Med; 2010 Jun; 181(11):1241-9. PubMed ID: 20299529
[TBL] [Abstract][Full Text] [Related]
47. Prolactin receptor expression in human hematopoietic tissues analyzed by flow cytofluorometry.
Dardenne M; de Moraes Mdo C; Kelly PA; Gagnerault MC
Endocrinology; 1994 May; 134(5):2108-14. PubMed ID: 8156910
[TBL] [Abstract][Full Text] [Related]
48. Phenotypic and functional characterization of freshly isolated and expanded canine regulatory T cells.
Knueppel A; Lange S; Sekora A; Altmann S; Freund M; Junghanss C
Exp Anim; 2011; 60(5):471-9. PubMed ID: 22041284
[TBL] [Abstract][Full Text] [Related]
49. Proliferation and mRNA expression of absorptive villous cell markers and mineral transporters in prolactin-exposed IEC-6 intestinal crypt cells.
Teerapornpuntakit J; Wongdee K; Thongbunchoo J; Krishnamra N; Charoenphandhu N
Cell Biochem Funct; 2012 Jun; 30(4):320-7. PubMed ID: 22281785
[TBL] [Abstract][Full Text] [Related]
50. Measurement of suppressor activity of T CD4⁺CD25⁺ T reg cells using bromodeoxyuridine incorporation assay.
Avalos-Martínez CE; Rodríguez-Alba JC; Berrón-Ruiz L; Romero-Ramírez H; Santos-Argumedo L; Jiménez-Zamudio LA; Domínguez-López ML; Vega-López A; García-Latorre E
Immunol Invest; 2013; 42(4):369-81. PubMed ID: 23883202
[TBL] [Abstract][Full Text] [Related]
51. Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma.
Chi LJ; Lu HT; Li GL; Wang XM; Su Y; Xu WH; Shen BZ
Clin Exp Immunol; 2010 Sep; 161(3):480-9. PubMed ID: 20646003
[TBL] [Abstract][Full Text] [Related]
52. Obtaining regulatory T cells from uraemic patients awaiting kidney transplantation for use in clinical trials.
Berglund D; Karlsson M; Biglarnia AR; Lorant T; Tufveson G; Korsgren O; Carlsson B
Clin Exp Immunol; 2013 Aug; 173(2):310-22. PubMed ID: 23607776
[TBL] [Abstract][Full Text] [Related]
53. [Immunological properties of prolactin].
Montero A; Giovannoni AG; Sen L
Medicina (B Aires); 2000; 60(4):515-20. PubMed ID: 11188961
[TBL] [Abstract][Full Text] [Related]
54. Clinical significance of Treg cell frequency in acute myeloid leukemia.
Yang W; Xu Y
Int J Hematol; 2013 Nov; 98(5):558-62. PubMed ID: 24142765
[TBL] [Abstract][Full Text] [Related]
55. Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland.
Glasow A; Breidert M; Haidan A; Anderegg U; Kelly PA; Bornstein SR
J Clin Endocrinol Metab; 1996 Aug; 81(8):3103-11. PubMed ID: 8768882
[TBL] [Abstract][Full Text] [Related]
56. Effects of prolactin on cloned human T-lymphocytes.
Dogusan Z; Martens N; Stinissen P; Hellings N; Demotte N; Hooghe R; Hooghe-Peters E
Endocrine; 2003; 20(1-2):171-6. PubMed ID: 12668883
[TBL] [Abstract][Full Text] [Related]
57. Structural and functional effects of high prolactin levels on injured endothelial cells: evidence for an endothelial prolactin receptor.
Merkle CJ; Schuler LA; Schaeffer RC; Gribbon JM; Montgomery DW
Endocrine; 2000 Aug; 13(1):37-46. PubMed ID: 11051045
[TBL] [Abstract][Full Text] [Related]
58. Requirement for prolactin during cell cycle regulated gene expression in cloned T-lymphocytes.
Clevenger CV; Sillman AL; Hanley-Hyde J; Prystowsky MB
Endocrinology; 1992 Jun; 130(6):3216-22. PubMed ID: 1534539
[TBL] [Abstract][Full Text] [Related]
59. Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response.
Feinerman O; Jentsch G; Tkach KE; Coward JW; Hathorn MM; Sneddon MW; Emonet T; Smith KA; Altan-Bonnet G
Mol Syst Biol; 2010 Nov; 6():437. PubMed ID: 21119631
[TBL] [Abstract][Full Text] [Related]
60. Prolactin receptors and the immune system.
Leite De Moraes MC; Touraine P; Gagnerault MC; Savino W; Kelly PA; Dardenne M
Ann Endocrinol (Paris); 1995; 56(6):567-70. PubMed ID: 8787345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
